Shilpa Medicare Limited Share Price NSE India S.E.

Equities

SHILPAMED

INE790G01031

Pharmaceuticals

Delayed NSE India S.E. 06:51:31 02/05/2024 BST 5-day change 1st Jan Change
547.3 INR -0.55% Intraday chart for Shilpa Medicare Limited +2.11% +65.40%

Financials

Sales 2022 11.47B 137M 10.97B Sales 2023 10.52B 126M 10.05B Capitalization 19.91B 239M 19.03B
Net income 2022 607M 7.27M 580M Net income 2023 -325M -3.89M -311M EV / Sales 2022 3.58 x
Net Debt 2022 6.58B 78.85M 6.29B Net Debt 2023 7.79B 93.36M 7.45B EV / Sales 2023 2.63 x
P/E ratio 2022
54.7 x
P/E ratio 2023
-61.3 x
Employees 1,179
Yield 2022
0.28%
Yield 2023
-
Free-Float 39.28%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.74%
1 week+2.11%
Current month+18.62%
1 month+10.39%
3 months+72.01%
6 months+57.07%
Current year+65.40%
More quotes
1 week
526.15
Extreme 526.15
561.60
1 month
463.05
Extreme 463.05
561.60
Current year
313.15
Extreme 313.15
561.60
1 year
228.50
Extreme 228.5
561.60
3 years
222.60
Extreme 222.6
670.40
5 years
208.10
Extreme 208.1
695.00
10 years
201.70
Extreme 201.7
786.90
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 19/11/87
Director of Finance/CFO - 30/05/21
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 63 19/11/87
Director/Board Member 58 01/09/21
Director/Board Member 63 01/09/21
More insiders
Date Price Change Volume
02/05/24 547.3 -0.55% 179 173
30/04/24 550.4 +2.58% 596,856
29/04/24 536.5 -1.39% 448,201
26/04/24 544 +2.48% 374,684
25/04/24 530.9 -0.04% 123,694

Delayed Quote NSE India S.E., May 02, 2024 at 06:51 am

More quotes
Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in research and development, manufacturing and sale of oncology drugs and formulations. Its products consist of oncology and non-oncology active pharmaceutical ingredients (APIs), oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. It supplies oncology APIs and intermediates. Its oncology/non-oncology APIs include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib HCL, and Irinotecan HCL Trihydrate for various regulated markets, including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India. It is also engaged in manufacturing and sale of Lenvatinib Capsules under the brand name Lenshil.
More about the company

Quarterly revenue - Rate of surprise